ISSUE: Managed entry schemes or “performance-based risk sharing arrangements” offer innovative payment models and involve a plan by which the performance of the product is tracked and the amount or level of reimbursement is based on the health and cost outcomes achieved. There is considerable uncertainty about the ultimate real-world performance of new technologies. MES or PBRSAs represent a platform of mechanisms that aim to reduce this uncertainty through greater investment in evidence collection while a technology is used within a health care system. However, “The hype around risk-sharing agreements has always seemed to outpace the accomplishments” (Neumann, 2013). OVERVIEW: In this issues panel we debate the value of managed entry schemes (MES). Professor Karnon will provide an overview of what it is that is trying to be achieved and when are these schemes desirable. Professor Karnon will also draw on experiences in Australia to consider the gap between what could be achieved and what is achieved with regards to MESs. It is well understood that no “one size fits all” when it comes to MESs implemented across the world. Professor Anh will provide the perspective from Korea who has an increasingly sophisticated health technology assessment approach. Whilst managed entry schemes may represent a logical advancement, Professor Anh will draw on his experience to discuss the challenges for implementing MES and the value they may represent in Korea. Dr Cook is the Associate Director of Health Economics, Bristol Myers Squibb Australia. Dr Cook will present the unique perspective of the value of MESs from industry. In particular, weighing –up the benefits of the potential flexibility of alternative evidence against the cost and limitations in data infrastructure.